Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing.
Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis.
The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice.
Key topics covered include:
Risk factors, prevention and sun safety education
Diagnosis, staging and grading
Surgical excision of melanoma lesions
Sentinel lymph node biopsy
Biological therapies, including immunotherapy and vaccination
Novel chemotherapy options
Treatment of metastasis
Prevention of recurrence
Patient care and quality of life
Melanoma Management delivers an accessible overview of current and future melanoma management options in a concise format that is ideal for the busy clinician. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including COPE, ICMJE and GPP3.
Journal metrics
Citation metrics
1.0 (2023) Impact Factor
2.5 (2023) 5 year IF
5.1 (2023) CiteScore (Scopus)
Q1 CiteScore Best Quartile
0.945 (2023) SNIP
0.945 (2023) SJR
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors
who are deciding where to submit their next manuscript for publication.
However, any one metric only tells a part of the story of a journal’s
quality and impact. Each metric has its limitations which means that it
should never be considered in isolation, and metrics should be used to
support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside
other qualitative factors such as a journal’s aims & scope, its
readership, and a review of past content published in the journal. In
addition, a single article should always be assessed on its own merits and
never based on the metrics of the journal it was published in.
Usage and acceptance rate data above are for the last full calendar year
and are updated annually in February. Speed data is updated every six
months, based on the prior six months. Citation metrics are updated
annually mid-year. Please note that some journals do not display all of
the following metrics
(find out why).
Usage:
the total number of times articles in the journal were viewed by users
of Taylor & Francis Online in the previous calendar year, rounded to the
nearest thousand.
Citation Metrics
Impact Factor*:
the average number of citations received by articles published in the
journal within a two-year window. Only journals in the Clarivate Science
Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI),
Arts and Humanities Citation Index (AHCI) and the Emerging Sources
Citation Index (ESCI) have an Impact Factor.
Impact Factor Best Quartile*:
the journal’s highest subject category ranking in the Journal Citation
Reports. Q1 = 25% of journals with the highest Impact Factors.
5 Year Impact Factor*:
the average number of citations received by articles in the journal
within a five-year window.
CiteScore (Scopus)†:
the average number of citations received by articles in the journal over
a four-year period.
CiteScore Best Quartile†:
the journal’s highest CiteScore ranking in a Scopus subject category. Q1
= 25% of journals with the highest CiteScores.
SNIP
(Source Normalized Impact per Paper):
the number of citations per paper in the journal, divided by citation
potential in the field.
SJR
(Scimago Journal Rank):
Average number of (weighted) citations in one year, divided by the
number of articles published in the journal in the previous three years.
Speed/acceptance
From submission to first decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision. Based on manuscripts receiving a
first decision in the last six months.
From submission to first post-review decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision if it is sent out for peer review.
Based on manuscripts receiving a post-review first decision in the last
six months.
From acceptance to online publication:
the average (median) number of days from acceptance of a manuscript to
online publication of the Version of Record. Based on articles published
in the last six months.
Acceptance rate:
articles accepted for publication by the journal in the previous
calendar year as percentage of all papers receiving a final decision.
Anja Boßerhoff, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany Mary Brady, Memorial Sloan Kettering Cancer Center, USA Vincenzo De Giorgi, University of Florence, Italy Soldano Ferrone, Massachusetts General Hospital, USA Jane Grant-Kls, University of Connecticut, US. Jean-Jacques Grob, Aix-Marseille Université, France Johan Hansson, Karolinska Institut, Sweden Meenhard Herlyn, Wistar Insititute, USA Peter Hersey, University of Sydney, Australia John M. Kirkwood, MD, University of Pittsburgh, and UPMC Hillman Cancer Center, USA James Larkin, Royal Marsden Hospital, UK Sancy Leachman, Oregon Health & Science University, USA Michele Maio, University Hospital of Siena, Italy Mario Mandalà, Papa Giovanni XXIII Hospital, Italy Daniela Massi, University of Florence, Italy Jane Messina, H. Lee Moffitt Cancer Center, USA Caroline Robert, Gustave Roussy Paris, France Richard Scolyer, Royal Prince Alfred Hospital and NSW Health Pathology, Australia Craig Slingluff Jr, University of Virginia Health System, USA Andrzej Slominski, University of Tennessee, USA Keiran Smalley, H. Lee Moffitt Cancer Center, USA Alessandro Testori, Istituto Europeo di Oncologia, Italy Jonathan Zager, H. Lee Moffitt Cancer Center, USA Iris Zalaudek, University of Graz, Austria
Open access
Melanoma Management is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
Increase the discoverability and readership of your article
Make an impact and reach new readers, not just those with easy access to a research library
Freely share your work with anyone, anywhere
Comply with funding mandates and meet the requirements of your institution, employer or funder
Rigorous peer review for every open access article
Article Publishing Charges (APC)
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110817/Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
![F1000Research. The Oncology Gateway. Accepting multiple article types. Submit now.]({"type":"image" , "src" : "/sda/112413/JournalAd-F1000-Oncology.jpg"})